Study identifies TBK1 as key to overcoming CAR T resistance

Russell W. Jenkins, MD, Ph.D., a physician investigator in the Krantz Family Center for Cancer Research at the Mass General Cancer Center and an assistant professor of Medicine at Harvard Medical School, is senior author of a new study in Cancer Immunology Research, “TBK1 is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids”.